# A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT02963493** · PHASE2 · COMPLETED · sponsor: **Oncopeptides AB** · enrollment: 157 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan flufenamide (Melflufen)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02963493
- **Lead sponsor:** Oncopeptides AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-28
- **Primary completion:** 2020-10-22
- **Final completion:** 2021-11-16
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2022-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963493, "A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02963493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*